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LETTERS TO THE EDITOR
p75 Neurotrophin Receptor Antagonist Retards Apoptosis-driven
Hair Follicle Involution (Catagen)
To the Editor:
Recently we have demonstrated that neurotrophins, a family of
structurally and functionally related polypeptides that include
nerve growth factor (NGF), neurotrophin (NT)-3, brain-derived
neurotrophic factor (BDNF), and NT-4, are involved in the con-
trol of apoptosis-driven hair follicle (HF) regression (catagen)
(Botchkarev et al, 1998, 1999). Speci¢cally, we showed that neuro-
trophins accelerate catagen most likely by stimulating the p75
kDa neurotrophin receptor (p75NTR), which is expressed in
the regressing outer root sheath and is known to mediate apopto-
sis when activated alone (Casaccia-Bonne¢l et al, 1996; Frade et al,
1996;Yaar et al, 1997; Botchkarev et al, 2000).
To determine if blocking ligand binding to p75NTR would
a¡ect catagen progression, we designed a cyclic peptide (CAT-
DIKGAEC) that mimics the p75NTR-binding loop of NGF.1
Binding studies con¢rmed that this peptide completely inhibited
125I-NGF-binding to p75NTR (Yaar et al, 2002).We therefore hy-
pothesized that this p75NTR antagonist may also prevent apop-
tosis in the HF that is mediated by neurotrophins, thus retarding
catagen.
To test this hypothesis, the e¡ect of the p75NTR antagonist
on catagen dynamics has been determined in murine skin organ
culture that lacks functional innervation. Organ culture of mur-
ine back skin was selected as an established model for studying
neurotrophin e¡ects on hair growth in vitro (Paus et al, 1994a;
Botchkarev et al, 1998, 1999, 2000). p75NTR antagonist was added
to mouse skin in organ culture at the stage when most HF were
in the process of initiating the anagenVI^catagen transformation
of the hair cycle, as well as to skin with more advanced catagen
development. Brie£y, biopsies were taken from the back skin of
8wk old C57BL/6 or p75NTR knockout mice (Lee et al, 1992) 17
or 18 d after anagen induction by depilation (Paus et al, 1990). Or-
gan cultures were maintained at an air^liquid interphase on gela-
tin gels (Li et al, 1992; Paus et al, 1994a) for 48 h in the presence of
one of the neurotrophins (NGF, BDNF, or NT-3), 1^100mM of
synthetic p75NTR antagonistic cyclic decapeptide alone or in
combination with one of the neurotrophins, or with diluent as
control.2-4
To determine whether p75NTR antagonist could block the
catagen-stimulatory e¡ect of neurotrophins, biopsies of C57BL/6
murine catagen skin were cultured in the presence of 100 mM of
the synthetic p75NTR antagonistic cyclic decapeptide or diluent.
Medium was also supplemented with one of the following:
250 ng mouse 2.5SNGF per ml (Boehringer Mannheim,
Germany), 50 ng human recombinant NT-3 per ml (Promega,
Madison,WI), or 5 ng human recombinant BDNF per ml (Pro-
mega). At the end of the incubation period, skin fragments were
washed repeatedly in PBS at 41C, ¢xed in 4% paraformaldehyde,
and embedded in para⁄n for routine histology and histomor-
phometry. The percentage of HF in each de¢ned catagen stage
was calculated using the ‘‘blind’’ method in eight to 10 biopsies
per group at  400 magni¢cation using a Zeiss Axioscope mi-
croscope, as described previously (Paus et al, 1994b).
In addition, the dynamics of catagen development was assessed
quantitatively, using a modi¢ed formula described previously
(Maurer et al, 1997; Botchkarev et al, 2000): D¼CI
1þCII2þCIII3þCIV 4þCV 5þCVI 6þCVII
7þCVIII 8, where CI^CVIII¼percent of HF at each stage of
catagen. Then, the acceleration or retardation of catagen develop-
ment was evaluated, taking a D-value from the corresponding
control experiment as 100%. All sections were analyzed at
 200 to  400 magni¢cation, and mean and SEM were calcu-
lated from pooled data. Di¡erences were judged as signi¢cant if
po0.05, as determined by the independent Student’s t test for un-
paired samples.
Quantitative histomorphometry revealed that the p75NTR
antagonist retarded catagen development in skin biopsies of
C57BL/6 mice. At day 17 post depilation there was a signi¢cant
increase in the number of HF in early catagen after incubation
with p75NTR antagonist (po0.05), compared with biopsies in-
cubated with vehicle control (data not shown). On average, cata-
gen was retarded by 15.972.6%. An even more profound
retardation of catagen development (by 3374.1%) was observed
when p75NTR antagonist was administered to skin biopsies
taken at day 18 post depilation. Here, we found a signi¢cant in-
crease (po0.05) of catagen II^III HF, compared with vehicle con-
trol where HF reached more advanced stages of catagen (Fig 1A^
C). Retardation of catagen was associated with a substantial in-
crease of skin thickness as a result of p75NTR antagonist treat-
ment (Fig 1B,C). In mice, skin thickness is strictly coupled to
distinct hair cycle stages and is maximal in anagen, whereas it is
signi¢cantly reduced during catagen (Mueller-Rover et al, 2001).
Therefore, reduction of skin thickness could be considered as
additional criterion of catagen development. Importantly, the
p75NTR antagonist did not alter catagen development in skin
specimens of p75NTR null mice that were taken on days 17^18
postdepilation (not shown). This strongly suggests that catagen in
the wild-type C57BL/6 mice is mediated, at least in part, through
p75NTR.
To determine, whether p75NTR antagonist can inhibit cata-
gen-stimulatory e¡ects of neurotrophins (Botchkarev et al, 1998,
1999), we supplemented organ cultures with the p75NTR antag-
onistic cyclic decapeptide and NGF, NT-3, or BDNF. In order to
compare results with previous data, skin biopsies were taken at
day 17 of the induced hair cycle, and neurotrophins were tested
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at the concentrations found as most e¡ective to promote catagen
in organ culture (Botchkarev et al, 1998, 1999, 2000).
The results of these experiments are summarized inTable I. In
line with previous results (Botchkarev et al, 1998, 1999, 2000),
NGF, NT-3, and BDNF each signi¢cantly (po0.05) enhanced
the percentage of HF in advanced catagen stages by 15^24%,
compared with vehicle control (Table I); however, in the pre-
sence of p75NTR antagonist, NGF, NT-3, and BDNF failed to
promote catagen development (Table I). Conversely, there was a
signi¢cant reduction (po0.05) in the number of HF in advanced
catagen stages in skin biopsies treated with combinations of
p75NTR antagonist and NGF, NT-3, or BDNF, as compared
with the biopsies treated with each neurotrophin alone and
peptide diluent. This suggests that the catagen-promoting action
of neurotrophins is signi¢cantly blocked by the administration
of p75NTR antagonist (Table I).
This corroborates previous evidence that neurotrophins stimu-
late catagen development predominantly via interaction with
p75NTR and identi¢es the p75NTR antagonist as a clinically
interesting, novel pharmacologic tool for the manipulation of
HF cycling.
For instance, such a peptide might be used to treat hair
disorders that are characterized by premature entry into catagen
(e.g., telogen e¥uvium, androgenetic alopecia, and alopecia
areata) (cf. Paus, 1996; Paus and Cotsarelis, 1999).
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Figure1. p75NTR antagonistic peptide inhibits HF regression.
Punch biopsies taken from C57BL/6 mouse back skin at day 18 of the de-
pilation-induced hair cycle (i.e., with all HF about to enter into the catagen
II^IV transformation) were incubated for 48 h in the presence of 1 or
100mM of cyclic p75NTR antagonistic decapeptide CATDIKGAEC1^4 or
with vehicle alone, and percentage of HF at each catagen stage was calcu-
lated. (A) Graph representing the percentage of HF in di¡erent stages of
catagen in skin biopsies incubated with p75NTR antagonist or diluent
(mean7SEM, n¼ 8^10 biopsies per group, Student’s t test, asterisks indi-
cate signi¢cant di¡erences, npo0.05). (B,C) Representative examples of
control skin biopsy (B) and biopsy incubated with 100 mM of p75NTR an-
tagonist peptide (C). Note that in the skin biopsy maintained with
p75NTR antagonist many HF are still in stages II^III (C, arrows) of catagen
development, whereas most HF are in catagen VI in control biopsy (B, ar-
rows). Also, despite the number of follicles in control and test skin has not
been changed, the skin is still substantially thicker in test biopsy (C) com-
pared with control (B), indicating about retardation of catagen after incuba-
tion with p75NTR antagonist (Paus et al, 1990, 1994b). DER, dermis;
PCM, panniculus carnosus muscle; SC, subcutis. Scale bar: 100mm.
Table I. Alterations in spontaneous catagen development in-
duced by p75NTR antagonist and by neurotrophins, or by
their combinations in skin organ culture (% of control)
Catagen inhibition Catagen stimulation
p75NTR antagonist 15.972.6%n ^
NGF ^ 15.871.8%n
p75NTR antagonistþNGF 0.870.1% ^
BDNF ^ 24.172.9%n
p75NTR antagonistþBDNF 1071.6% ^
NT-3 ^ 1972.2%n
p75NTR antagonistþNT-3 4.370.9% ^
Asterisks indicate signi¢cant di¡erences to control (Student’s t test, p o 0.05).
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